The estimated Net Worth of Bruce Eaton is at least $1.53 Milione dollars as of 5 December 2023. Dr Eaton owns over 103 units of Editas Medicine Inc stock worth over $282,710 and over the last 3 years he sold EDIT stock worth over $154,832. In addition, he makes $1,093,133 as Exec. VP & Chief Bus. Officer at Editas Medicine Inc.
Dr has made over 22 trades of the Editas Medicine Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 103 units of EDIT stock worth $1,123 on 5 December 2023.
The largest trade he's ever made was selling 3,307 units of Editas Medicine Inc stock on 13 February 2023 worth over $31,979. On average, Dr trades about 470 units every 35 days since 2021. As of 5 December 2023 he still owns at least 74,791 units of Editas Medicine Inc stock.
You can see the complete history of Dr Eaton stock trades at the bottom of the page.
Dr. Bruce E. Eaton Ph.D. is the Exec. VP & Chief Bus. Officer at Editas Medicine Inc.
As the Exec. VP & Chief Bus. Officer of Editas Medicine Inc, the total compensation of Dr D at Editas Medicine Inc is $1,093,133. There are 2 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.
Dr D is 67, he's been the Exec. VP & Chief Bus. Officer of Editas Medicine Inc since . There are no older and 16 younger executives at Editas Medicine Inc.
Bruce's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr e Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: